Author: Ramona Adams|| Date Published: December 7, 2016
SRI International has secured a seven-year, $150 million contract from the National Institutes of Health to provide development services for candidate HIV prevention products from investigator-initiated studies or from partnerships with other companies and organizations.
SRI said Tuesday its biosciences division will manufacture and characterize drug products to support the development of microbicide and non-vaccine pre-exposure agents through preclinical and clinical studies for the NIH’s National Institute of Allergy and Infectious Diseases and the Division of AIDS.
The company will also support activities that the Food and Drug Administration requires to move products into clinical tests.
Gita Shankar, an SRI director, has led a project to develop a multipurpose HIV prevention microbicide bioadhesive gel under an NIAID grant the company received in 2010.
SRI also produced drug products and supplied clinical sites with microbicides and contraceptive controls between 2000 and 2004.
Redhawk Federal Solutions has acquired Twenty8 Technology to expand its data interoperability and artificial intelligence and machine learning engineering capabilities.…
Antenna Research Associates has appointed Jay Abendroth, a seasoned defense electronics executive, as chief growth officer to lead business development…
Precise Systems has appointed Michael “Mike” Risik as vice president of business development. The Lexington Park, Maryland-based company said Wednesday Risik will…
SRI International has secured a seven-year, $150 million contract from the National Institutes of Health to provide development services for candidate HIV prevention products from investigator-initiated studies or from partnerships with other companies and organizations.
